Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma

Ishikawa,Toru; Abe,Satoshi; Watanabe,Takayuki; Nozawa,Yujiro; Sano,Tomoe; Iwanaga,Akito; Seki,Keiichi; Honma,Terasu; Yoshida,Toshiaki

doi:10.3892/mco.2016.998

Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma

Authors:
- Toru Ishikawa
- Satoshi Abe
- Takayuki Watanabe
- Yujiro Nozawa
- Tomoe Sano
- Akito Iwanaga
- Keiichi Seki
- Terasu Honma
- Toshiaki Yoshida
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata 950‑1104, Japan
Published online on: August 22, 2016 https://doi.org/10.3892/mco.2016.998
Pages: 511-516
Copyright: © Ishikawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transcatheter arterial chemoembolization (TACE) is the standard therapy for Barcelona Clinic Liver Cancer (BCLC) classification intermediate stage B hepatocellular carcinoma (HCC). However, other transcatheter methods, such as transcatheter arterial infusion (TAI), also play an important role in the treatment of advanced HCC. Although it has been reported that TAI with a high concentration of a fine‑powder formulation of cisplatin (DDP‑H) reduced intrahepatic recurrence and improved survival, the combined use of TAI with DDP‑H and TACE has not yet been investigated. The aim of this study was to evaluate which TACE chemotherapeutic agent in combination with DDP‑H TAI contributes more to improved survival in BCLC‑B HCC. Survival was analyzed in 55 patients who underwent DDP‑H TAI and TACE for BCLC‑B HCC. The patients were classified into two groups; Epirubicin was used as the TACE agent in 29 patients, whereas miriplatin was used in 26 patients. The cumulative survival rates at 1 and 2 years were 66.4 and 36.0% in the epirubicin and 95.8 and 61.30% in the miriplatin group, respectively. Survival time was significantly prolonged in the miriplatin group compared with that in the epirubicin group. Multivariate analysis identified Child‑Pugh classification and up‑to‑seven criteria as factors affecting survival. In addition, the selection of miriplatin as the TACE chemoagent was the treatment factor that most significantly affected survival. Thus, double‑platinum therapy with DDP‑H TAI and miriplatin TACE may be a useful treatment strategy for improving survival in BCLC-B HCC patients.

View Figures

View References

1	Bruix J and Sherman M: American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bruix J and Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
3	Tommasini M, Colombo M, Sangiovanni A, Orefice S, Bignami P, Doci R and Gennari L: Intrahepatic doxorubicin in unresectable hepatocellular carcinoma. The unfavorable role of cirrhosis. Am J Clin Oncol. 9:8–11. 1986. View Article : Google Scholar : PubMed/NCBI
4	Ichida T, Kato M, Hayakawa A, Watanabe M, Igarashi K, Hata K, Doya Y, Miura M, Sato H and Asakura H: Treatment of hepatocellular carcinoma with a CDDP-epirubicin-lipiodol suspension: A pilot clinico-pharmacological study. Cancer Chemother Pharmacol. 31:(Suppl). S51–S54. 1992. View Article : Google Scholar : PubMed/NCBI
5	Aoyama K, Tsukishiro T, Okada K, Tsuchida T, Aiba N, Nambu S, Miyabayashi C, Yasuyama T, Higuchi K and Watanabe A: Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinoma. Cancer Chemother Pharmacol. 31:(Suppl). S55–S59. 1992. View Article : Google Scholar : PubMed/NCBI
6	Colleoni M, Gaion F, Liessi G, Mastropasqua G and Nelli P: Arterial chemoembolization with epirubicin in unresectable hepatocellular carcinoma in cirrhosis. Oncol Rep. 1:1171–1175. 1994.PubMed/NCBI
7	Ohnishi K, Tsuchiya S, Nakayama T, Hiyama Y, Iwama S, Goto N, Takashi M, Ohtsuki T, Kono K, Nakajima Y, et al: Arterial chemoembolization of hepatocellular carcinoma with mitomycin C microcapsules. Radiology. 152:51–55. 1984. View Article : Google Scholar : PubMed/NCBI
8	Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, Kojima J, Ishikawa O, Ohigashi H, Furukawa H, et al: A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer. 60:1194–1203. 1987. View Article : Google Scholar : PubMed/NCBI
9	Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T and Kamimura T: Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. Cancer. 117:4018–4025. 2011. View Article : Google Scholar : PubMed/NCBI
10	Ishikawa T, Kubota T, Abe S, Watanabe Y, Sugano T, Inoue R, Iwanaga A, Seki K, Honma T and Yoshida T: Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival. Ann Oncol. 25:1379–1384. 2014. View Article : Google Scholar : PubMed/NCBI
11	Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K and Takashima S: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 148:397–401. 1983. View Article : Google Scholar : PubMed/NCBI
12	Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M and Kogayashi K: Small hepatocellular carcinoma: Treatment with subsegmental transcatheter arterial embolization. Radiology. 188:79–83. 1993. View Article : Google Scholar : PubMed/NCBI
13	Kim HC, Lee JH, Chung JW, Kang B, Yoon JH, Kim YJ, Lee HS, Jae HJ and Park JH: Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein. J Vasc Interv Radiol. 24:274–283. 2013. View Article : Google Scholar : PubMed/NCBI
14	Tanaka M, Yoshida S and Kimura K: Mechanism of inhibition of DNA polymerases by 4′-epiadriamycin and 4′-O-tetrahydropyranyladriamycin. Gan. 74:829–836. 1983.PubMed/NCBI
15	Nagasue N, Yukaya H, Okamura J, Kuroda C, Kubo Y, Hirai K, Tanikawa K, Okita K, Ando K and Tamura K: Intra-arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma. Epirubicin study group for hepatocellular carcinoma. Cancer & chemotherapy. 13:2786–2792. 1986.(In Japanese).
16	Yoshikawa M, Saisho H, Ebara M, Iijima T, Iwama S, Endo F, Kimura M, Shimamura Y, Suzuki Y, Nakano T, et al: A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol. 33:(Suppl). S149–S152. 1994. View Article : Google Scholar : PubMed/NCBI
17	Maeda M, Uchida NA and Sasaki T: Liposoluble platinum (II) complexes with antitumor activity. Jpn J Cancer Res. 77:523–525. 1986.PubMed/NCBI
18	Kishimoto S, Ohtani A, Fukuda H, Fukushima S and Takeuchi Y: Relation between intracellular accumulation and cytotoxic activity of cis-[((1R, 2R)-1,2-cyclohexanediamine-N, N')bis(myristato)]platinum(II) suspended in Lipiodol. Biol Pharm Bull. 26:683–686. 2003. View Article : Google Scholar : PubMed/NCBI
19	Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N and Nishikaku F: Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 64:473–483. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hanada M, Baba A, Tsutsumishita Y, Noguchi T and Yamaoka T: Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci. 100:189–194. 2009. View Article : Google Scholar : PubMed/NCBI
21	Okusaka T, Okada S, Nakanishi T, Fujiyama S and Kubo Y: Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs. 22:169–176. 2004. View Article : Google Scholar : PubMed/NCBI
22	Miyayama S, Yamashiro M, Shibata Y, Hashimoto M, Yoshida M, Tsuji K, Toshima F and Matsui O: Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol. 30:263–270. 2012. View Article : Google Scholar : PubMed/NCBI
23	Handa T, Imai Y, Sugawara K, Chikayama T, Nakazawa M, Ando S, Hamaoka K, Inao M, Nakayama N and Mochida S: Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin. Hepatol Res. 44:1072–1080. 2014. View Article : Google Scholar : PubMed/NCBI
24	Kamimura K, Suda T, Tamura Y, Takamura M, Yokoo T, Igarashi M, Kawai H, Yamagiwa S, Nomoto M and Aoyagi Y: Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. BMC Gastroenterol. 12:1272012. View Article : Google Scholar : PubMed/NCBI